RELMADA THERAPEUTICS, INC. Defined Contribution Plan, Cost
RELMADA THERAPEUTICS, INC. (RLMD) reported Defined Contribution Plan, Cost of $109.50 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. defined contribution plan, cost for the quarter ending 2026-06-30 was $54.30K, a 2.45% increase year-over-year.
- RELMADA THERAPEUTICS, INC. defined contribution plan, cost for the quarter ending 2026-03-31 was $55.20K, a 15.72% increase year-over-year.
- RELMADA THERAPEUTICS, INC. defined contribution plan, cost for the quarter ending 2025-12-31 was $25.16K, a 10.12% decline year-over-year.
- RELMADA THERAPEUTICS, INC. defined contribution plan, cost for the quarter ending 2025-09-30 was $50.50K, a 33.25% increase year-over-year.
- RELMADA THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2025 was $176.37K, a 30.35% increase from fiscal 2024.
- RELMADA THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2024 was $135.30K, a 4.03% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2023 was $140.98K.
- RELMADA THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2020 was $90.69K, a 351.63% increase from fiscal 2019.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $54.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $109.50K 10-Q · filed 2026-08-06 | $134.66K derived: sum of 3 quarters · filed 2026-08-06 | $185.16K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $55.20K 10-Q · filed 2026-05-12 | $80.36K derived: sum of 2 quarters · filed 2026-05-12 | $130.87K derived: sum of 3 quarters · filed 2026-05-12 | $183.87K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $25.16K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $75.67K derived: sum of 2 quarters · filed 2026-03-19 | $128.66K derived: sum of 3 quarters · filed 2026-08-06 | $176.37K 10-K · filed 2026-03-19 |
| 2025-09-30 | $50.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $103.50K derived: sum of 2 quarters · filed 2026-08-06 | $151.20K 10-Q · filed 2025-11-13 | $179.20K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $100.70K 10-Q · filed 2026-08-06 | $128.70K derived: sum of 3 quarters · filed 2026-08-06 | $166.60K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $47.70K 10-Q · filed 2026-05-12 | $75.70K derived: sum of 2 quarters · filed 2026-05-12 | $113.60K derived: sum of 3 quarters · filed 2026-05-12 | $148.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $65.90K derived: sum of 2 quarters · filed 2026-03-19 | $100.30K derived: sum of 3 quarters · filed 2026-03-19 | $135.30K 10-K · filed 2026-03-19 |
| 2024-09-30 | $37.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $72.30K derived: sum of 2 quarters · filed 2025-11-13 | $107.30K 10-Q · filed 2025-11-13 | $129.48K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $34.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $69.40K 10-Q · filed 2025-08-07 | $91.58K derived: sum of 3 quarters · filed 2025-08-07 | $129.48K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $35.00K 10-Q · filed 2025-05-12 | $57.18K derived: sum of 2 quarters · filed 2025-05-12 | $95.08K derived: sum of 3 quarters · filed 2025-05-12 | $135.58K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $22.18K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $60.08K derived: sum of 2 quarters · filed 2025-03-27 | $100.58K derived: sum of 3 quarters · filed 2025-03-27 | $140.98K 10-K · filed 2025-03-27 |
| 2023-09-30 | $37.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $78.40K derived: sum of 2 quarters · filed 2024-11-07 | $118.80K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $40.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $80.90K 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $40.40K 10-Q · filed 2024-05-08 | |||
| 2021-03-31 | $40.32K 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $90.69K 10-K · filed 2021-03-24 | |||
| 2020-03-31 | $8.06K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $10.26K 10-K · filed 2021-03-24 | $20.08K 10-K · filed 2021-03-24 | ||
| 2019-06-30 | $18.85K 10-K · filed 2021-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |